logo Hematology/Oncology Research Studies: Open for Enrollment Date: 10/22/18

Category: SICKLE CELL DISEASE

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-Beta-0 Thalassemia)

NCT#/Phase: NCT03401112
Phase 2a
IRB#: 2018-021
Description: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-0 Thalassemia)
Inclusion: Individuals between 18 to 50 years of age with sickle cell disease (Hb SS, or HbS/Beta0-thalassemia who have not had more than 3 episodes of vaso-occlusive crisis (VOC) in the past 12 months, baseline hemoglobin (Hb) level >= 6 and <= 11g/dL are eligible. Participants taking hydroxyurea must be on a stable dose for at least 3 months prior to enrollment.
Enrollment Status: Open for enrollment
Sponsor: Imara
Principal Investigator(s): Carolyn Hoppe, MD
Contact(s): Smith, Kacie

Study Link: #

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000